IND is the abbreviation for Investigative New Drug, a term used by the FDA. This designates a drug that is under investigation that has not yet been given market authority but has likely been determined in a Phase I study to be reasonably safe. With an IND the developing drug company is allowed to provide the drug to those who may benefit and have an informed consent that is supervised by an Institutional Review Board. The results of taking the drug is then tracked by the company and this data can be reviewed by the regulatory authorities and used to supplement the clinical trial data for market authority. See further information under our Early Access programme.
